Trial Profile

A Confirmatory Study of LT1001, an Extended-Release Analgesic Injection

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dinalbuphine-sebacate (Primary)
Indications Pain
Focus Registrational; Therapeutic Use
Sponsors Lumosa Therapeutics

Most Recent Events

10 Dec 2019 New trial record
03 Dec 2019 According to a Lumosa Therapeutics media release, this confirmatory trial will be conducted before the submission of a new drug application (NDA) to the US FDA for marketing authorization approval.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com